Mavacamten medical insurance inclusion status query

Mavacamten (mavacamten), as a new drug that has been widely discussed in the cardiovascular field in recent years, has been officially launched in China and has been included in the National Medical Insurance List. A key change in this policy is to translate the high cost of innovative drugs into affordable long-term treatments, providing wider access to patients with oHCM. The medical insurance-limited population is clearly adult patients with New York Heart Association (NYHA) grade II–III obstructive hypertrophic cardiomyopathy (HCM). This is because this type of patients has quality of life impairment and is still in the reversible stage. Drug intervention can significantly improve the obstruction load and exercise capacity.

The important significance of this medical insurance inclusion is to significantly reduce the financial burden. Mavaceta is a long-term management drug with a high unit price. Without reimbursement support, it will be difficult for many patients to maintain long-term treatment. After being included in medical insurance, its actual payment ratio is reduced, making it a sustainable treatment plan, helping to intervene early and reduce the risk of disease progression. Policy-oriented specifications include different dose packaging of 2.5mg, 5mg, 10mg and 15mg, which facilitates individualized initiation, adjustment and maintenance programs based on patients' different metabolic characteristics, myocardial structure and hemodynamic performance.

Medical insurance policies have also given positive impetus to clinical use, prompting medical institutions to strengthen standardized management of myocardial hypertrophy, such as gradually promoting imaging monitoring follow-up procedures and improving primary hospitals' risk identification capabilities for oHCM patients, making drug use more accurate and safer. In addition, since the dosage of Mavaceta needs to be dynamically adjusted based on efficacy and cardiac function, medical insurance reimbursement encourages more patients to receive regular follow-up visits so that the drug can be adjusted in time before risks such as decreased contractility occur.

The core of medical insurance restrictions are "obstructive" and "grade II-III", which means that patients with non-obstructive HCM and very mild or severe symptoms are not covered by reimbursement. This is in line with the indication range of current drug research data and also takes into account the balance between costs and benefits of national medical insurance. In the future, if overseas studies show that it performs more clearly in non-obstructive HCM, population expansion, or long-term follow-up, the domestic medical insurance catalog may be further adjusted.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/